DIARYLHYDANTOIN COMPOUNDS AS ANDROGEN RECEPTOR ANTAGONISTS FOR TREATMENT OF CANCER
申请人:The Regents of the University of California
公开号:EP3106162A1
公开(公告)日:2016-12-21
The present invention relates to a particular diarylhydantoin compound acting by reducing the androgen-receptor(AR) activity. The compound is thus for use in treatment of diseases such as hormone refractory cancer, prostate cancer, benign prostate hyperplasia, breast cancer and ovarian cancer.
TREATMENT OF HYPERPROLIFERATIVE DISORDERS WITH DIARYLHYDANTOIN COMPOUNDS
申请人:Sawyers Charles L.
公开号:US20120295944A1
公开(公告)日:2012-11-22
The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
Treatment of hyperproliferative disorders with diarylhydantoin compounds
申请人:The Regents of the University of California
公开号:US08183274B2
公开(公告)日:2012-05-22
The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.